London – October 16, 2026 -- The global ADHD drugs market will grow from USD 14.11 billion in 2025 to USD 22.79 billion by 2035, a compound annual growth rate of 4.91%, according to Credence Research Inc. The figures are the research firm's proprietary estimates, not audited sales totals.
North America holds 60% of value while Asia Pacific grows fastest at 6.34%
North America accounted for 60.0% of 2025 market value. Europe followed with 20.0%, Asia Pacific with 13.0%, Latin America with 4.0% and the Middle East and Africa with 3.0%.
Credence attributes Asia Pacific's 6.34% annual growth to better recognition and access in Japan, Australia and, increasingly, China, from a comparatively small revenue base. In Europe, reimbursement systems and lower net medicine prices restrain value per patient.
Methylphenidate takes 30% of drug-type revenue, retail pharmacies 68% of channel value
Methylphenidate represented 30.0% of 2025 drug-type value, supported by extended-release brands and generics. Children and adolescents generated 56.0% of demographic revenue, while adults are the faster-growing patient group.
Retail pharmacies produced 68.0% of channel revenue. Online fulfillment is growing from a smaller base under controlled-substance rules.
Adult diagnosis and differentiated dosing drive demand
Expanded adult assessment and specialty mental health services are enlarging the identified patient population. Later-life diagnoses can lengthen the duration of medicine use, though demand still depends on clinical evaluation and continued access to prescribing.
Once-daily formulations, nighttime dosing and pediatric-friendly suspensions address adherence and dosing difficulties. Clinical evidence, safety labeling and reimbursement decisions determine uptake of new therapies.
Otsuka's Simtriyo and generic lisdexamfetamine reshape competition
Otsuka announced U.S. approval of Simtriyo (centanafadine) in July 2026 for eligible adults and children aged 6 and older. The product is a triple reuptake inhibitor.
Increased generic lisdexamfetamine availability has intensified competition for established branded stimulants. Differentiated long-acting products and reliable manufacturing may gain share where shortages limit routine prescribing.
Takeda, Johnson & Johnson and Novartis hold legacy stimulant franchises that generic rivals are challenging. Supernus competes in nonstimulants, while Tris Pharma and Collegium focus on differentiated formulations. Generic makers compete on price and access to controlled active ingredients.
Production quotas and FDA warnings constrain supply and prescribing
Controlled-substance quotas on stimulant production cause periodic shortages that can prevent patients from filling prescriptions. Suppliers must coordinate authorized active ingredient supply and local distribution while maintaining regulatory compliance.
In June 2025, the FDA required expanded warnings on weight loss risk with extended-release stimulants in children younger than six, an age group for which those products are not approved.
Credence expects generic competition to restrain revenue per prescription through 2035. It says manufacturers with resilient supply chains, evidence-backed formulations and good payer access may be better placed than suppliers dependent on a single legacy stimulant brand.